Influence of pidotimod combined with conventional drug therapy on the infection status and immune function of children with recurrent respiratory tract infection

Objective: To study the influence of pidotimod combined with conventional drug therapy on the infection status and immune function of children with recurrent respiratory tract infection. Methods: A total of 118 children with recurrent respiratory tract infection who were treated in the hospital between January 2015 and January 2017 were collected and divided into control group and observation group by random number table method, 59 cases in each group. Control group received conventional therapy, and observation group received pidotimod combined with conventional therapy. The differences in serum levels of inflammatory mediators, acute phase proteins and Th1/Th2 cytokines were compared between the two groups before and after treatment. Results: Before treatment, the differences in serum levels of inflammatory mediators, acute phase proteins and Th1/Th2 cytokines were not statistically significant between the two groups. after 1 week of treatment, serum TNF-α, PCT, CRP, PAB, TRF and IL-4 contents of both groups of children were lower than those before treatment while IFN-γ contents as well as IFN-γ/ IL-4 levels were higher than those before treatment, and serum TNF-α, PCT, CRP, PAB, TRF and IL-4 contents of observation group were lower than those of control group while IFN-γ content as well as IFN-γ/ IL-4 level was higher than those of control group. Conclusion: Pidotimod combined with conventional drug therapy can effectively inhibit the infection status and optimize the Th1/Th2 cellular immune function of children with recurrent respiratory tract infection.